Ensysce Biosciences Inc. Common Stock (ENSC)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn money, have durable competitive advantages, and sell below intrinsic value. Ensysce does not yet fit that mold. It is a clinical-stage pharmaceutical company with eight employees, developing opioid prodrugs through its TAAP and MPAR platforms. In fiscal 2025, the year ended 2025-12-31, it reported revenue of $5.1 million and a net loss of $10.2 million, or diluted EPS of -$3.98. In fiscal 2024, revenue was $5.2 million and net loss was $8.0 million; in fiscal 2023, revenue was $2.2 million and net loss was $10.6 million. More recent quarters remain unprofitable: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $1.2 million and net loss was $2.6 million. FairStock calculations show trailing free cash flow of -$9.0 million and an FCF yield of -80.5% against the 2026-10-13 market cap of $11.1 million. Its Piotroski F-Score is 1/9 and Altman Z-Score is -67.90, signs of serious financial fragility. Debt is modest at D/E 0.11, but that does not offset the cash burn. At the 2026-10-13 close of $0.57, FairStock calculates P/B of 0.40 and P/E of -0.22. A low price-to-book can tempt a bargain hunter, but persistent losses and dependence on clinical/regulatory outcomes make book value an unreliable margin of safety. The given Lynch category is none because it lost money in each of the last four years. I see speculation, not a Graham-style bargain.

In plain English: Ensysce Biosciences is a small drug company developing prescription pain medicines that are designed to be harder to abuse or overdose on. The business looks weak today: it has been losing money and burning cash, with no profits in recent years. At $0.57 on 2026-10-13, the price may look very low, but because earnings and cash flow are negative, it is not clearly cheap versus the numbers—it is mainly a bet on future drug testing.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer